Paper Details

  1. Home
  2. Paper Details

Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease.

Author: ClearyT G, ContriniM, DevotoS, GómezH, LiuH, LópezE, MurrayB E, PradoD, WolojM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ceftibuten was as effective as trimethoprim-sulfamethoxazole in treating dysentery in 22 children. Ceftibuten was more effective in patients with TMP-SMX-resistant organisms.
Paper Details　
Original Abstract of the Article :
In a prospective randomized study at two clinical sites, ceftibuten was compared with trimethoprim-sulfamethoxazole (TMP-SMX), both given orally for a period of 5 days, for the treatment of dysentery. Twenty-two children were found to have bacillary dysentery caused by Shigella and/or enteroinvasive...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1523076

データ提供：米国国立医学図書館（NLM）

Ceftibuten vs. Trimethoprim-Sulfamethoxazole: A Battle Against Shigella and Enteroinvasive E. coli

Shigella and enteroinvasive E. coli are bacterial culprits behind dysentery, a nasty intestinal infection. This study compares the effectiveness of two oral antibiotics, ceftibuten and trimethoprim-sulfamethoxazole (TMP-SMX), in treating dysentery in children. The researchers aimed to determine which antibiotic is more effective and safe for treating this common intestinal infection. The study included children with bacillary dysentery caused by Shigella and/or enteroinvasive E. coli.

Ceftibuten: A Strong Contender Against Resistant Strains

The study found that ceftibuten was at least as effective as TMP-SMX in treating dysentery, particularly against strains that were resistant to TMP-SMX. This is like a skilled desert traveler navigating treacherous terrain, finding a safe and reliable route where others have failed. The study also noted that ceftibuten was well-tolerated by the children, with no reported side effects.

Treating Dysentery Effectively: The Importance of Targeted Antibiotics

The study's findings highlight the importance of choosing the right antibiotic for treating dysentery. It's essential to consider the specific organism causing the infection and its susceptibility to various antibiotics. This is like choosing the right camel for a desert journey, considering the terrain and climate. Choosing the right antibiotic can help ensure effective treatment and minimize the risk of complications.

Dr. Camel's Conclusion

This research provides valuable insights into the treatment of dysentery, a common and potentially serious infection. By understanding the efficacy and safety of different antibiotics, healthcare providers can make informed decisions to ensure the best possible outcomes for their patients. It's a reminder that, like navigating a vast and unpredictable desert, treating infections requires careful consideration and a nuanced approach.

Date :
  1. Date Completed 1992-10-09
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

1523076

DOI: Digital Object Identifier

1523076

Related Literature

Article Analysis
・Side Effects of ceftibuten
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.